BACKGROUND: CXC chemokine receptor (CXCR4) has been shown to be expressed in a subset of acute myeloid leukemia (AML) patients and is correlated with a poor prognosis. CXCR4 expression appears to be an independent prognostic factor for survival in a heterogeneous group of AML patients. To better assess its significance, we analyzed CXCR4 expression in a group of AML patients. METHODS: The prognostic value of CXCR4 expression in 53 patients with AML presenting between 2003 and 2008 was analyzed. Formalin-fixed, paraffin-embedded bone marrow biopsy or clot sections were stained using immunohistochemical methods. RESULTS: CXCR4 was expressed in 26 patients (49.1%). A patient age of less than 60 years (P=0.023), achievement of complete remission after induction therapy (P<0.001), and no CXCR4 expression (P=0.010) were all associated with better progression-free survival (PFS). Among mutations of NPM1, CEBPA, FLT3 ITD, and FLT3 D835 and expression of CXCR4, only CXCR4 expression was associated with PFS (P=0.010; by log-rank test). By multivariate analysis, CXCR4 expression was an independent prognostic factor (P=0.001 for PFS and P=0.001 for overall survival). CXCR4 expression in patients with a normal karyotype was detected in 15 of 22 patients (68.2%, relative ratio 4.46, P=0.035). Expression of CXCR4 in normal-karyotype AML showed inferior PFS (median 2.0 vs. 10.7 mo, P=0.026) and had a trend toward inferior overall survival (median 10.8 vs. 14.0 mo, P=0.058). CONCLUSIONS: These results suggest that CXCR4 expression is associated with poor prognosis in patients with AML. Specifically, CXCR4 expression is common in normal-karyotype AML and is a marker of more aggressive disease in this population. CXCR4 expression could be incorporated into the risk assessment of patients with AML.
BACKGROUND: CXC chemokine receptor (CXCR4) has been shown to be expressed in a subset of acute myeloid leukemia (AML) patients and is correlated with a poor prognosis. CXCR4 expression appears to be an independent prognostic factor for survival in a heterogeneous group of AMLpatients. To better assess its significance, we analyzed CXCR4 expression in a group of AMLpatients. METHODS: The prognostic value of CXCR4 expression in 53 patients with AML presenting between 2003 and 2008 was analyzed. Formalin-fixed, paraffin-embedded bone marrow biopsy or clot sections were stained using immunohistochemical methods. RESULTS:CXCR4 was expressed in 26 patients (49.1%). A patient age of less than 60 years (P=0.023), achievement of complete remission after induction therapy (P<0.001), and no CXCR4 expression (P=0.010) were all associated with better progression-free survival (PFS). Among mutations of NPM1, CEBPA, FLT3 ITD, and FLT3 D835 and expression of CXCR4, only CXCR4 expression was associated with PFS (P=0.010; by log-rank test). By multivariate analysis, CXCR4 expression was an independent prognostic factor (P=0.001 for PFS and P=0.001 for overall survival). CXCR4 expression in patients with a normal karyotype was detected in 15 of 22 patients (68.2%, relative ratio 4.46, P=0.035). Expression of CXCR4 in normal-karyotype AML showed inferior PFS (median 2.0 vs. 10.7 mo, P=0.026) and had a trend toward inferior overall survival (median 10.8 vs. 14.0 mo, P=0.058). CONCLUSIONS: These results suggest that CXCR4 expression is associated with poor prognosis in patients with AML. Specifically, CXCR4 expression is common in normal-karyotype AML and is a marker of more aggressive disease in this population. CXCR4 expression could be incorporated into the risk assessment of patients with AML.
Authors: Ana C Viñado; Isabel A Calvo; Itziar Cenzano; Danel Olaverri; Miguel Cocera; Patxi San Martin-Uriz; Juan P Romero; Amaia Vilas-Zornoza; Laura Vera; Nuria Gomez-Cebrian; Leonor Puchades-Carrasco; Livia E Lisi-Vega; Iñigo Apaolaza; Pablo Valera; Elisabeth Guruceaga; Froilan Granero-Molto; Purificacion Ripalda-Cemborain; Tamara J Luck; Lars Bullinger; Francisco J Planes; José J Rifon; Simón Méndez-Ferrer; Rushdia Z Yusuf; Ana Pardo-Saganta; Felipe Prosper; Borja Saez Journal: Leukemia Date: 2022-05-26 Impact factor: 12.883
Authors: Ho Cheol Shin; Jongwon Seo; Byung Woog Kang; Joon Ho Moon; Yee Soo Chae; Soo Jung Lee; Yoo Jin Lee; Seoae Han; Sang Kyung Seo; Jong Gwang Kim; Sang Kyun Sohn; Tae-In Park Journal: Korean J Intern Med Date: 2014-10-31 Impact factor: 2.884
Authors: Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger Journal: Theranostics Date: 2015-03-01 Impact factor: 11.556
Authors: Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield; Susan P Whitman; Jessica Kohlschmidt; Kati Maharry; Stefano Volinia; Krzysztof Mrózek; Deedra Nicolet; Sebastian Schwind; Heiko Becker; Klaus H Metzeler; Jason H Mendler; Ann-Kathrin Eisfeld; Andrew J Carroll; Bayard L Powell; Thomas H Carter; Maria R Baer; Jonathan E Kolitz; Il-Kyoo Park; Richard M Stone Journal: Leukemia Date: 2013-12-11 Impact factor: 11.528